This program is intended for hematologists/oncologists and other multidisciplinary care team members who treat patients with lymphomas.
This program aims to improve learners’ knowledge, confidence, and competence in integrating the latest clinical guidance and expert recommendations in the application of CAR T-cell therapy for the treatment of lymphomas into clinal practice.
Michael R. Bishop, MD
Professor of Medicine, Director
Section of Hematology/Oncology,
Cellular Therapy Program
University of Chicago
Michael R. Bishop, MD: consultant/advisor/speaker: CRISPR Therapeutics, Kite/Gilead, Novartis; researcher: Autolus.
Kathleen Dorritie, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
UPMC Hillman Cancer Center,
University of Pittsburgh
Kathleen Dorritie, MD: consultant/advisor/speaker: Bristol Myers Squibb; researcher (paid to institution): Genmab, Juno/Bristol Myers Squibb, Kite/Gilead, Janssen.
Julie M. Vose, MD, MBA
Newmann M. and Milde E. Harris Professor
Department of Internal Medicine
University of Nebraska Medical Center
Julie M. Vose, MD, MBA: consultant/advisor/speaker: AbbVie, MEI Pharma; researcher: Epizyme, Kite, Loxo, Novartis.